DEXTROMETHORPHAN HYDROBROMIDE

US Approved OTC

First approved in 1954

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H25NO.BrH.H2O
Molecular Weight	370.324
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DEXTROMETHORPHAN HYDROBROMIDE

Structure Search

SMILES

O.Br.[H][C@]12CCCC[C@]13CCN(C)[C@H]2CC4=CC=C(OC)C=C34

InChI

InChIKey=STTADZBLEUMJRG-IKNOHUQMSA-N

InChI=1S/C18H25NO.BrH.H2O/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H;1H2/t15-,17+,18+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H25NO
Molecular Weight	271.3972
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27139517
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2694543 http://www.who.int/medicines/areas/quality_safety/5.1Dextromethorphan_pre-review.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/25420446

Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive for almost 40 years. It has attracted attention due to its anticonvulsant and neuroprotective properties. It is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high-affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives and is used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown. Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome. Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan, which is rapidly glucuronidated and unable to cross the blood-brain barrier.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 63 Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15723099	Agonist 2678		205.0 nM [Ki]
Glutamate [NMDA] receptor subunit 3A 21 Target ID: CHEMBL4787 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2897648	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cough 106 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf	Primary		Approved 8429	MUCINEX DM Approved Use Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive: temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you get to sleep Launch Date 2004
Pseudobulbar affect 7 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26000221	Primary		Approved 8429	NUEDEXTA Approved Use NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Launch Date 2010

C_max

Value	Dose	Co-administered	Analyte	Population
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
95.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
123.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
124.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
599 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
709 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
32 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1049 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
133.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1000.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
933.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2898 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3608 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
68 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217	30 mg single, oral dose: 30 mg route of administration: oral experiment type: single co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: healthy age: adults sex: food status:

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
50 mg 4 times / day steady, oral Dose: 50 mg, 4 times / day Route: oral Route: steady Dose: 50 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	unhealthy, 19-52 years n = 16 Health Status: unhealthy Condition: chronic intractable partial onset seizures Age Group: 19-52 years Sex: M+F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	Sources: https://pubmed.ncbi.nlm.nih.gov/8741125
960 mg 1 times / day multiple, oral Highest studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	unhealthy, 19-67 years n = 11 Health Status: unhealthy Condition: Huntington's disease Age Group: 19-67 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	Sources: https://pubmed.ncbi.nlm.nih.gov/2529964
120 mg single, oral Recommended Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	healthy, 26.5 years n = 40 Health Status: healthy Age Group: 26.5 years Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	Sources: https://pubmed.ncbi.nlm.nih.gov/26294136
900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	Other AEs: Ischemic colitis... Other AEs: Ischemic colitis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	Other AEs: Lethargy, Ataxia... Other AEs: Lethargy (1 patient) Ataxia (1 patient) Nystagmus (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

AEs

AE	Significance	Dose	Population
Ischemic colitis	1 patient	900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
Ataxia	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Lethargy	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Nystagmus	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781	inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP2E1 882	P-gp 1537	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://www.eurekaselect.com/66423/article/lack-interaction-nmda-receptor-antagonists-dextromethorphan-and-dextrorphan-p	no
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/11602530/ Page: 2.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000OtherR.pdf#page=63 Page: 63.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4470	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4470
ZINC	ZINC000003201907	http://zinc15.docking.org/substances/ZINC000003201907

PubMed

Title	Date	PubMed
Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist.	1991 Mar-Apr	1685312
Visual hallucinations after combining fluoxetine and dextromethorphan.	1992 Oct	1530079
Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice.	1999 Jul 14	10448923
[Acute cholestatic hepatitis induced by dextromethorphan].	1999 Oct	10592673
Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (Ultram): a case study.	2000	10985875
Mimicking gene defects to treat drug dependence.	2000	10911933
The antitussive activity of delta-opioid receptor stimulation in guinea pigs.	2000 Feb	10640321
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.	2001	12001656
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.	2001 Aug	11505218
Prediction models in the design of neural network based ECG classifiers: a neural network and genetic programming approach.	2002	11846893
A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition.	2002 Aug 22	12151071
Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.	2002 Dec	12438554
Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity.	2002 Jul-Aug	12078863
Biotechnology in the Medicon Valley.	2002 May	11981549
Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex.	2003 Feb 15	12576146
Total and corrected antioxidant capacity in hemodialyzed patients.	2003 Jul 1	12837136
Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.	2003 Sep-Oct	12928596
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.	2004 Dec	15383492
Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children.	2004 Jul	15199075
Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens.	2004 Jul 16	15240036
Validated assays for human cytochrome P450 activities.	2004 Jun	15155557
Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes.	2004 May	15370959
Bladder emptying over a period of 10-45 years after a traumatic spinal cord injury.	2004 Nov	15326470
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.	2004 Nov	15286053
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.	2004 Oct 26	15505150
[Dextromethorphan enhances analgesic activity of propacetamol--experimental study].	2005	17037292
Epigenetic silencing of DSC3 is a common event in human breast cancer.	2005	16168112
The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.	2005 Apr	15723099
Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity.	2005 Feb	15356218
Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.	2005 Jun	15988119
Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris.	2005 Nov	16222729
Side effects of dextromethorphan abuse, a case series.	2005 Sep	16122622
Cluster formation as a tool for development in Medicon Valley.	2006 Jan-Feb	16485399
Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure.	2007	17903238
Cough mixture abuse as a novel cause of folate deficiency: a prospective, community-based, controlled study.	2007 Apr	17488670
Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats.	2007 Apr	17225166
Effects of dextromethorphan on dopamine dependent behaviours in rats.	2007 Aug	17877148
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.	2007 Aug	17470523
Treatment of the common cold.	2007 Feb 15	17323712
[Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method].	2007 Jun	17702393
Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.	2007 May 9	17418993
Prior exposure to uninfected mosquitoes enhances mortality in naturally-transmitted West Nile virus infection.	2007 Nov 14	18000543
Effect of sodium ozagrel on the activity of rat CYP2D6.	2007 Nov 14	17651725
Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain.	2007 Spring	17461892
Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.	2008 Apr	18221780
Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening.	2008 Jul	18420780
Effects of repeated cycles of sterilisation on the mechanical characteristics of titanium miniplates for osteosynthesis.	2008 Sep	18336967
Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice.	2009 Apr 1	19189960
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy.	2009 Jan-Feb	19344034
[Bone anchored hearing aids (BAHA)].	2009 Mar	19343390

Patents

Sample Use Guides

In Vivo Use Guide

15-30 mg 3 to 4 times per day (cough) 20-30 mg twice daily (pseudobulbar affect)

Route of Administration: Oral

In Vitro Use Guide

In vitro studies pre- and immature oligodendroglial (OLN-93) cells were subjected to hyperoxic conditions for 48 h after pre-treatment with increasing doses of dextromethorphan.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:04:42 GMT 2023` Edited by `admin` on `Fri Dec 15 15:04:42 GMT 2023`
Record UNII	9D2RTI9KYH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEXTROMETHORPHAN HYDROBROMIDE

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF MUCINEX DM

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF NUEDEXTA

Common Name

English

BROMFED-DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE [USP-RS]

Common Name

English

ST. JOSEPH COUGH SYRUP

Brand Name

English

AZEDIPAMIN

Common Name

English

AUVELITY COMPONENT DEXTROMETHORPHAN HYDROBROMIDE

Brand Name

English

DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF BROMANATE DM

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE HYDRATE [JAN]

Common Name

English

BROMANATE DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF PHERAZINE DM

Common Name

English

DIMETANE-DX COMPONENT DEXTROMETHORPHAN HYDROBROMIDE

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE HYDRATE

Common Name

English

AVP-923 COMPONENT DEXTROMETHORPHAN HYDROBROMIDE

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE [EP MONOGRAPH]

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF AUVELITY

Brand Name

English

DEXTROMETHORPHAN HYDROBROMIDE [WHO-IP]

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE

Common Name

English

3-METHOXY-17-METHYL-9.ALPHA.,13.ALPHA.,14.ALPHA.-MORPHINAN HBR MONOHYDRATE

Common Name

English

MORPHINAN, 3-METHOXY-17-METHYL-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-, HBR, MONOHYDRATE

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF BROMFED-DM

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF DIMETANE-DX

Common Name

English

MORPHINAN, 3-METHOXY-17-METHYL-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-, HYDROBROMIDE, MONOHYDRATE

Common Name

English

CALMOCITENE

Common Name

English

DRIXORAL COUGH

Common Name

English

DEXTROMETHORPHANI HYDROBROMIDUM [WHO-IP]

Common Name

English

SIMASEDAN

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE OROS TABLETS

Common Name

English

DEXTROMETHORPHAN HBR

Common Name

English

MUCINEX DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF PROMETHAZINE DM

Common Name

English

NUEDEXTA COMPONENT DEXTROMETHORPHAN HYDROBROMIDE

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE [ORANGE BOOK]

Common Name

English

BENYLIN DM

Common Name

English

Dextromethorphan hydrobromide monohydrate [WHO-DD]

Common Name

English

3-Methoxy-17-methyl-9α,13α,14α-morphinan hydrobromide monohydrate

Common Name

English

DEXTROMETHORPHAN HYDROBROMIDE [VANDF]

Common Name

English

PROMETHAZINE DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE

Common Name

English

NUEDEXTA

Brand Name

English

DEXTROMETHORPHAN HYDROBROMIDE [USP MONOGRAPH]

Common Name

English

ROMILAR

Common Name

English

PEDIACARE 1

Common Name

English

PHERAZINE DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 341.14